About
DNA Script is a life-science technology company that has developed the SYNTAX® platform — a benchtop DNA printer powered by proprietary enzymatic DNA synthesis (EDS) technology. Unlike conventional chemical phosphoramidite methods, EDS produces longer, more complex DNA sequences with higher fidelity, enabling researchers to unlock new experimental possibilities. The SYNTAX® platform is designed for labs that need reliability, speed, and ease of use. Scientists can synthesize high-quality, ready-to-use single-stranded DNA (ssDNA) oligonucleotides overnight — fully in-house — without waiting days or weeks for commercial suppliers. This dramatically accelerates design-build-test-learn cycles, particularly in synthetic biology, genomics, and molecular biology research. The platform is supported by SYNTAX® Kits that provide all necessary reagents for seamless synthesis runs, a comprehensive knowledge hub, application notes, publications, and dedicated technical support. DNA Script serves a broad range of customers including CROs, core genomics facilities, biotech startups, pharmaceutical companies, and government research agencies worldwide. With distributor agreements expanding into Latin America, Japan, and South Korea (as of 2026), DNA Script is growing its global footprint. The company is headquartered in Le Kremlin-Bicêtre, France, and partners with world-class institutions such as Imperial College London's London Biofoundry.
Key Features
- SYNTAX® DNA Printer: A benchtop instrument that synthesizes ssDNA oligonucleotides in-house using enzymatic DNA synthesis, delivering ready-to-use results overnight.
- Enzymatic DNA Synthesis (EDS) Technology: Proprietary EDS method enables the production of longer, more complex DNA sequences with higher fidelity compared to conventional chemical synthesis.
- Overnight Turnaround: Produce high-quality oligos within hours, eliminating the multi-day or multi-week wait times associated with outsourcing to commercial DNA suppliers.
- SYNTAX® Kits: Pre-packaged reagent kits optimized for seamless operation with the SYNTAX® platform, ensuring consistent and reproducible synthesis runs.
- Global Support & Resources: Comprehensive knowledge hub, application notes, publications, technical support, and a growing distributor network across North America, Europe, Latin America, Japan, and South Korea.
Use Cases
- Synthetic biology labs accelerating design-build-test-learn cycles by synthesizing custom DNA on demand overnight
- Pharmaceutical companies producing oligonucleotide tools for drug discovery and development in-house without supplier delays
- CROs and core genomics facilities offering rapid, high-quality DNA synthesis services to multiple research clients
- Biotech startups maintaining full workflow control and IP security by synthesizing proprietary sequences in-house
- Government research agencies and biofoundries running high-throughput biological research programs requiring reliable on-demand DNA access
Pros
- Full Workflow Control: In-house synthesis eliminates dependency on external suppliers, giving researchers autonomy over timelines and project execution.
- Speed and Reliability: Overnight oligo production with consistent, high-quality output accelerates research cycles significantly.
- Scalable Across Institution Types: Suited for diverse environments — from biotech startups and CROs to pharma giants and governmental research agencies.
Cons
- High Upfront Capital Cost: As an enterprise-grade instrument, the SYNTAX® platform requires significant capital investment, which may be prohibitive for small labs or academic groups with limited budgets.
- Niche Application Focus: The platform is purpose-built for DNA oligonucleotide synthesis, so its utility is limited to labs with relevant molecular biology or synthetic biology workflows.
- Reagent Dependency: Ongoing use requires purchasing SYNTAX® Kits, creating recurring reagent costs on top of the instrument investment.
Frequently Asked Questions
What is the SYNTAX® platform?
The SYNTAX® platform is DNA Script's benchtop DNA printer that uses enzymatic DNA synthesis (EDS) technology to produce single-stranded DNA oligonucleotides in-house, overnight, without relying on commercial synthesis suppliers.
How does enzymatic DNA synthesis differ from chemical synthesis?
Enzymatic DNA synthesis (EDS) uses biological enzymes rather than chemical phosphoramidite reactions to build DNA strands. This approach enables longer, more complex sequences with higher fidelity and is more environmentally friendly.
Who is the SYNTAX® platform designed for?
It is designed for CROs, core genomics facilities, biotech companies, pharmaceutical companies, and governmental research agencies that need reliable, on-demand access to high-quality DNA oligonucleotides.
How quickly can the SYNTAX® platform produce oligos?
The SYNTAX® platform produces ready-to-use ssDNA oligonucleotides overnight, allowing researchers to move forward with experiments the next day rather than waiting days or weeks for commercial orders.
Is the SYNTAX® platform available globally?
Yes. DNA Script has established distributor agreements covering North America, Europe, Latin America, Japan, and South Korea, with ongoing global expansion efforts.
